

**Measure #119 (NQF 0062): Diabetes: Medical Attention for Nephropathy – National Quality Strategy**  
**Domain: Effective Clinical Care**

**2017 OPTIONS FOR INDIVIDUAL MEASURES:**  
**REGISTRY ONLY**

**MEASURE TYPE:**  
Process

**DESCRIPTION:**  
The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period

**INSTRUCTIONS:**  
This measure is to be reported a minimum of **once per performance period** for all patients with diabetes mellitus seen during the performance period. This measure may be reported by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

**Measure Reporting:**  
The listed denominator criteria is used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions allowed by the measure. The quality-data codes listed do not need to be submitted for registry-based submissions; however, these codes may be submitted for those registries that utilize claims data.

**DENOMINATOR:**  
Patients 18 - 75 years of age with diabetes with a visit during the measurement period

**Denominator Criteria (Eligible Cases):**  
Patients aged 18 years to 75 years on date of encounter

**AND**

**Diagnosis for diabetes (ICD-10-CM):** E10.10, E10.11, E10.21, E10.22, E10.29, E10.311, E10.319, E10.3211, E10.3212, E10.3213, E10.3219, E10.3291, E10.3292, E10.3293, E10.3299, E10.3311, E10.3312, E10.3313, E10.3319, E10.3391, E10.3392, E10.3393, E10.3399, E10.3411, E10.3412, E10.3413, E10.3419, E10.3491, E10.3492, E10.3493, E10.3499, E10.3511, E10.3512, E10.3513, E10.3519, E10.3521, E10.3522, E10.3523, E10.3529, E10.3531, E10.3532, E10.3533, E10.3539, E10.3541, E10.3542, E10.3543, E10.3549, E10.3551, E10.3552, E10.3553, E10.3559, E10.3591, E10.3592, E10.3593, E10.3599, E10.36, E10.37X1, E10.37X2, E10.37X3, E10.37X9, E10.39, E10.40, E10.41, E10.42, E10.43, E10.44, E10.49, E10.51, E10.52, E10.59, E10.610, E10.618, E10.620, E10.621, E10.622, E10.628, E10.630, E10.638, E10.641, E10.649, E10.65, E10.69, E10.8, E10.9, E11.00, E11.01, E11.21, E11.22, E11.29, E11.311, E11.319, E11.3211, E11.3212, E11.3213, E11.3219, E11.3291, E11.3292, E11.3293, E11.3299, E11.3311, E11.3312, E11.3313, E11.3319, E11.3391, E11.3392, E11.3393, E11.3399, E11.3411, E11.3412, E11.3413, E11.3419, E11.3491, E11.3492, E11.3493, E11.3499, E11.3511, E11.3512, E11.3513, E11.3519, E11.3521, E11.3522, E11.3523, E11.3529, E11.3531, E11.3532, E11.3533, E11.3539, E11.3541, E11.3542, E11.3543, E11.3549, E11.3551, E11.3552, E11.3553, E11.3559, E11.3591, E11.3592, E11.3593, E11.3599, E11.36, E11.37X1, E11.37X2, E11.37X3, E11.37X9, E11.39, E11.40, E11.41, E11.42, E11.43, E11.44, E11.49, E11.51, E11.52, E11.59, E11.610, E11.618, E11.620, E11.621, E11.622, E11.628, E11.630, E11.638, E11.641, E11.649, E11.65, E11.69, E11.8, E11.9, E13.00, E13.01, E13.10, E13.11, E13.21, E13.22, E13.29, E13.311, E13.319, E13.3211, E13.3212, E13.3213, E13.3219, E13.3291, E13.3292, E13.3293, E13.3299, E13.3311, E13.3312, E13.3313, E13.3319, E13.3391, E13.3392, E13.3393, E13.3399, E13.3411, E13.3412, E13.3413, E13.3419, E13.3491, E13.3492, E13.3493, E13.3499, E13.3511, E13.3512, E13.3513, E13.3519, E13.3521, E13.3522, E13.3523, E13.3529, E13.3531, E13.3532, E13.3533, E13.3539, E13.3541, E13.3542, E13.3543, E13.3549, E13.3551, E13.3552, E13.3553, E13.3559, E13.3591, E13.3592, E13.3593, E13.3599, E13.36, E13.37X1, E13.37X2, E13.37X3, E13.37X9, E13.39, E13.40, E13.41, E13.42, E13.43, E13.44, E13.49, E13.51, E13.52, E13.59, E13.610,

E13.618, E13.620, E13.621, E13.622, E13.628, E13.630, E13.638, E13.641, E13.649, E13.65, E13.69, E13.8, E13.9, O24.011, O24.012, O24.013, O24.019, O24.02, O24.03, O24.111, O24.112, O24.113, O24.119, O24.12, O24.13, O24.311, O24.312, O24.313, O24.319, O24.32, O24.33, O24.811, O24.812, O24.813, O24.819, O24.82, O24.83

**AND**

**Patient encounter during the performance period (CPT or HCPCS):** 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, G0402, G0438, G0439

**AND NOT**

**DENOMINATOR EXCLUSION:**

**Patients who use hospice services any time during the measurement period:** G9715

**NUMERATOR:**

Patients with a screening for nephropathy or evidence of nephropathy during the measurement period

**Numerator Instructions:** This measure is looking for a nephropathy screening test or evidence of nephropathy.

**Numerator Options:**

***Performance Met:***

Positive microalbuminuria test result documented and reviewed **(3060F)**

**OR**

***Performance Met:***

Negative microalbuminuria test result documented and reviewed **(3061F)**

**OR**

***Performance Met:***

Positive macroalbuminuria test result documented and reviewed **(3062F)**

**OR**

***Performance Met:***

Documentation of treatment for nephropathy (eg, patient receiving dialysis, patient being treated for ESRD, CRF, ARF, or renal insufficiency, any visit to a nephrologist) **(3066F)**

**OR**

***Performance Met:***

Patient receiving angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) therapy **(G8506)**

**OR**

***Performance Not Met:***

Nephropathy screening was not performed, reason not otherwise specified **(3060F or 3061F or 3062F with 8P)**

**RATIONALE:**

As the seventh leading cause of death in the U.S., diabetes kills approximately 75,000 people a year (CDC FastStats 2015). Diabetes is a group of diseases marked by high blood glucose levels, resulting from the body's inability to produce or use insulin (CDC Statistics 2014, ADA Basics 2013). People with diabetes are at increased risk of serious health complications including vision loss, heart disease, stroke, kidney failure, amputation of toes, feet or legs, and premature death. (CDC Fact Sheet 2014).

In 2012, diabetes cost the U.S. an estimated \$245 billion: \$176 billion in direct medical costs and \$69 billion in reduced productivity. This is a 41 percent increase from the estimated \$174 billion spent on diabetes in 2007 (ADA Economic 2013).

In 2011, diabetes accounted for 44% of new kidney failure cases. In the same year, 49,677 diabetics started treatment for kidney failure and 228,924 people of all ages with kidney failure due to diabetes were living on chronic dialysis or with a kidney transplant (CDC Statistics, 2014).

### **CLINICAL RECOMMENDATION STATEMENTS:**

American Diabetes Association (2015):

#### Screening

- At least once a year, quantitatively assess urinary albumin (eg, urine albumin-to-creatinine ratio [UACR]) and estimated glomerular filtration rate (eGFR) in patients with type 1 diabetes duration of greater than or equal to 5 years and in all patients with type 2 diabetes. (Level of evidence: B)

#### Treatment

- An angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) is not recommended for the primary prevention of diabetic kidney disease in patients with diabetes who have normal blood pressure and normal UACR (<30 mg/g). (Level of evidence: B)

- Either an ACE inhibitor or ARB is suggested for the treatment of the nonpregnant patient with modestly elevated urinary albumin excretion (30-299 mg/day) (Level of evidence: C) and is recommended for those with urinary albumin excretion  $\geq$ 300 mg/day. (Level of evidence: A)

- When ACE inhibitors, ARBs, or diuretics are used, monitor serum creatinine and potassium levels for the development of increased creatinine or changes in potassium. (Level of evidence: E)

- Continued monitoring of UACR in patients with albuminuria is reasonable to assess progression of diabetic kidney disease. (Level of evidence: E)

American Association of Clinical Endocrinologists (2015):

- Beginning 5 years after diagnosis in patients with type 1 diabetes (if diagnosed before age 30) or at diagnosis in patients with type 2 diabetes and those with type 1 diabetes diagnosed after age 30, annual assessment of serum creatinine to determine the estimated glomerular filtration rate (eGFR) and urine albumin excretion rate (AER) should be performed to identify, stage, and monitor progression of diabetic nephropathy (Grade C; best evidence level 3).

- Patients with nephropathy should be counseled regarding the need for optimal glycemic control, blood pressure control, dyslipidemia control, and smoking cessation (Grade B; best evidence level 2).

- In addition, they should have routine monitoring of albuminuria, kidney function electrolytes, and lipids (Grade B; best evidence level 2).

- Associated conditions such as anemia and bone and mineral disorders should be assessed as kidney function declines (Grade D; best evidence level 4).

- Referral to a nephrologist is recommended well before the need for renal replacement therapy (Grade D; best evidence level 4).

### **COPYRIGHT:**


These performance measures were developed and are owned by the National Committee for Quality Assurance ("NCQA"). These performance measures are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures. NCQA holds a copyright in this measure and can rescind or alter this measure at any time. Users of the measure shall not have the right to alter, enhance, or otherwise modify the measure and shall not disassemble, recompile, or reverse engineer the

source code or object code relating to the measure. Anyone desiring to use or reproduce the measure without modification for a noncommercial purpose may do so without obtaining any approval from NCQA. All commercial uses must be approved by NCQA and are subject to a license at the discretion of NCQA. Use by health care providers in connection with their own practices is not commercial use. A "commercial use" refers to any sale, license, or distribution of a measure for commercial gain, or incorporation of a measure into any product or service that is sold, licensed, or distributed for commercial gain, even if there is no actual charge for inclusion of the measure. ©2004-2016 National Committee for Quality Assurance, all rights reserved.

Performance measures developed by NCQA for CMS may look different from the measures solely created and owned by NCQA.

CPT® contained in the Measures specifications is copyright 2004-2016 American Medical Association.

**2017 Registry Individual Measure Flow**  
**#119 NQF #0062: Diabetes: Medical Attention for Neuropathy**



\*See the posted Measure Specification for specific coding and instructions to report this measure.

NOTE: Reporting Frequency: Patient-process

CPT only copyright 2016 American Medical Association. All rights reserved.  
 The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.

v1

**2017 Registry Individual Measure Flow**  
**#119 NQF #0062: Diabetes: Medical Attention for Neuropathy**

**SAMPLE CALCULATIONS:**

**Data Completeness=**

$$\frac{\text{Performance Met (a}^1+\text{a}^2+\text{a}^3+\text{a}^4+\text{a}^5=4 \text{ patients)} + \text{Performance Not Met (c=3 patients)}}{\text{Eligible Population / Denominator (d=8 patients)}} = \frac{7 \text{ patients}}{8 \text{ patients}} = 87.50\%$$

**Performance Rate=**

$$\frac{\text{Performance Met (a=4 patients)}}{\text{Data Completeness Numerator (7 patients)}} = \frac{4 \text{ patients}}{7 \text{ patients}} = 57.14\%$$

\*See the posted Measure Specification for specific coding and instructions to report this measure.

CPT only copyright 2016 American Medical Association. All rights reserved.  
The measure diagrams were developed by CMS as a supplemental resource to be used in conjunction with the measure specifications. They should not be used alone or as a substitution for the measure specification.

NOTE: Reporting Frequency: Patient-process

v1

**2017 Registry Individual Measure Flow**  
**#119 NQF #0062: Diabetes: Medical Attention for Neuropathy**

Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in reporting this Individual Measure.

1. Start with Denominator
2. Check Patient Age:
  - a. If Age equal to 18 to 75 years of age on Date of Service equals No during the measurement period, do not include in Eligible Patient Population. Stop Processing.
  - b. If Age equal to 18 to 75 years of age on Date of Service equals Yes during the measurement period, proceed to Check Patient Diagnosis.
3. Check Patient Diagnosis:
  - a. If Diagnosis of Diabetes as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
  - b. If Diagnosis of Diabetes as Listed in the Denominator equals Yes, proceed to Check Encounter Performed.
4. Check Encounter Performed:
  - a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Patient Population. Stop Processing.
  - b. If Encounter as Listed in the Denominator equals Yes, proceed to Check Patients Who Use Hospice Services Any Time During the Measurement Period.
5. Check Patients Who Use Hospice Services Any Time During the Measurement Period:
  - a. If Patients Who Use Hospice Services Any Time During the Measurement Period No, include in the Eligible population.
  - b. If Patients Who Use Hospice Services Any Time During the Measurement Period equals Yes, do not include in Eligible Patient Population. Stop Processing.
6. Denominator Population:
  - a. Denominator population is all Eligible Patients in the denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 8 patients in the sample calculation.
7. Start Numerator
8. Check Positive Microalbuminuria Test Result Documented and Reviewed:
  - a. If Microalbuminuria Test Result Documented and Reviewed equals Yes, include in Data Completeness Met and Performance Met.
  - b. Data Completeness Met and Performance Met letter is represented as Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a1 equals 1 patient in Sample Calculation.
  - c. If Microalbuminuria Test Result Documented and Reviewed equals No, proceed to Negative Microalbuminuria Test Result Documented and Reviewed.

9. Check Negative Microalbuminuria Test Result Documented and Reviewed:
  - a. If Negative Microalbuminuria Test Result Documented and Reviewed equals Yes, include in Data Completeness Met and Performance Met.
  - b. Data Completeness Met and Performance Met letter is represented as Data Completeness and the Performance Rate in the Sample Calculation listed at the end of this document. Letter a2 equals 1 patient in the Sample Calculation.
  - c. If Negative Microalbuminuria Test Result Documented and Reviewed equals No, proceed to Positive Macroalbuminuria Test Result Documented and Reviewed.
10. Check Positive Macroalbuminuria Test Result Documented and Reviewed:
  - a. If Positive Macroalbuminuria Test Result Documented and Reviewed equals Yes, include in Data Completeness Met and Performance Met.
  - b. Data Completeness Met and Performance Met letter is represented as Data Completeness and the Performance Rate in the Sample Calculation listed at the end of this document. Letter a3 equals 1 patient in the Sample Calculation.
  - c. If Positive Macroalbuminuria Test Result Documented and Reviewed equals No, proceed to Documentation of Treatment for Nephropathy.
11. Check Documentation of Treatment for Nephropathy:
  - a. If Documentation of Treatment for Nephropathy equals Yes, include in the Data Completeness Met and Performance Met.
  - b. Data Completeness Met and Performance Met letter is represented as Data Completeness and the Performance Rate in the Sample Calculation listed at the end of this document. Letter a4 equals 1 patient in the Sample Calculation.
  - c. If Documentation of Treatment for Nephropathy equals No, proceed to Patient Receiving ACE Inhibitor or ARB Therapy.
12. Check Patient Receiving ACE Inhibitor or ARB Therapy:
  - a. If Patient Receiving ACE Inhibitor or ARB Therapy equals Yes, include in the Data Completeness Met and Performance Met.
  - b. Data Completeness Met and Performance Met letter is represented as Data Completeness and the Performance Rate in the Sample Calculation listed at the end of this document. Letter a5 equals 0 patients in the Sample Calculation.
  - c. If Patient Receiving ACE Inhibitor or ARB Therapy equals No, proceed to Nephropathy Screening Not Performed, Reason Not Specified.
13. Check Nephropathy Screening Not Performed, Reason Not Specified:
  - a. If Nephropathy Screening Not Performed, Reason Not Specified equals Yes, include in the Data Completeness Met and Performance Not Met.
  - b. Data Completeness Met and Performance Not Met letter is represented as Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 3 patients in the Sample Calculation.

- c. If Nephropathy Screening Not Performed, Reason Not Specified equals No, proceed to Data Completeness Not Met.

14. Check Data Completeness Not Met:

- a. If Data Completeness Not Met equals No, Quality Data Code or equivalent not reported. 1 patient has been subtracted from the Data Completeness numerator in the sample calculation.

**SAMPLE CALCULATIONS:**

**Data Completeness=**

$$\frac{\text{Performance Met (a}^1+\text{a}^2+\text{a}^3+\text{a}^4+\text{a}^5=4 \text{ patients)} + \text{Performance Not Met (c=3 patients)}}{\text{Eligible Population / Denominator (d=8 patients)}} = \frac{7 \text{ patients}}{8 \text{ patients}} = 87.50\%$$

**Performance Rate=**

$$\frac{\text{Performance Met (a=4 patients)}}{\text{Data Completeness Numerator (7 patients)}} = \frac{4 \text{ patients}}{7 \text{ patients}} = 57.14\%$$